ARTELO BIOSCIENCES, INC. Payments to Acquire Debt Securities, Available-for-sale
ARTELO BIOSCIENCES, INC. (ARTL) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-25.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2024-03-25
- ARTELO BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-12-31 was $0.00.
- ARTELO BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-09-30 was $0.00.
- ARTELO BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-06-30 was $0.00.
- ARTELO BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- ARTELO BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ARTELO BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $499.00K.
- ARTELO BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for fiscal 2021 was $0.00.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 4 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $0.00 derived: sum of 3 quarters · filed 2024-03-25 | $0.00 10-K · filed 2024-03-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 4 quarters · filed 2024-03-25 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $0.00 derived: sum of 3 quarters · filed 2024-03-25 | $0.00 derived: sum of 4 quarters · filed 2024-03-25 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $0.00 derived: sum of 3 quarters · filed 2024-03-25 | $0.00 derived: sum of 4 quarters · filed 2024-03-25 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $0.00 derived: sum of 3 quarters · filed 2024-03-25 | $499.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $499.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $499.00K 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $499.00K 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | $1.52M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | ||||
| 2021-08-31 | $0.00 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |